Chemerin in Obese Patients with Nonalcoholic Fatty Liver Disease with or without Prediabetes

Abstract

Chemerin is one of the recently discovered adipokines closely related with white adipose tissue and insulin resistance (IR) in obesity, type 2 diabetes mellitus (T2DM), and nonalcoholic fatty liver disease (NAFLD), but some of these data remain controversial. This study evaluated the relationship between serum chemerin levels, prediabetes and other biochemical and clinical parameters in obese patients with NAFLD. A total of 79 obese NAFLD patients without ($n=41$) and with prediabetes ($$n=38$$) were included. Serum chemerin was measured using ELISA method. Chemerin correlated with body mass index (BMI) ($$r=0.320$$, $$p<0.01$$), hip circumference ($$r=0.296$$, $$p<0.05$$) and visceral adiposity index (VAI) ($$r=0.297$$, $$p<0.05$$). Chemerin strongly correlated with hepatic steatosis index (HSI) ($$r=0.550$$, $$p<0.01$$). Chemerin is adipokine, which has a significant, but yet not unequivocal role in the metabolic process related with obesity, insulin resistance and NAFLD. In this study we were not able to find an association of serum chemerin levels and prediabetes. There were correlations with BMI, hip circumference, Visceral adiposity index and Hepatic steatosis index.